Answers are grounded in this paper and cite their sources.
Retrospective cohort study explores thrombocytopenia incidence in women with HER2-positive breast cancer, indicating it occurs moderately without significant treatment disruption.
e23379 Background: Trastuzumab, alone or with pertuzumab, is standard adjuvant therapy for HER2-positive breast cancer. Real-world evidence describing the incidence, clinical course, and management impact of trastuzumab-induced thrombocytopenia (TIT) is limited. Methods: Multicenter retrospective cohort study across three UAE infusion centers (2016–2024). Electronic records of 87 women receiving adjuvant trastuzumab (IV/SC; originator or biosimilar) with or without pertuzumab were reviewed. All patients had platelet recovery after (neo)adjuvant chemotherapy (baseline > 150×10^9/L). TIT was defined as any platelet count < 150×10^9/L after HER2-targeted therapy initiation and graded by CTCAE v4.0. We assessed onset cycle, platelet nadir, recurrence (multi-cycle drops), transfusion requirement, and management actions (delay, discontinuation, regimen change). Predictors were explored using univariable and multivariable logistic regression. Results: TIT occurred in 35.6% and was typically early (median onset cycle 3). Events were predominantly mild (Grade 1: 29), with rare higher-grade events (Grade 2: 1; Grade 4: 1; no Grade 3). Mean platelet nadir was 140.1×10^9/L (SD 28.5; range 17–276). Recurrent/multi-cycle platelet drops occurred in 16/87 (18.4%). Platelet transfusion was required in 8% of TIT cases. Treatment impact was limited: > 90% continued HER2-targeted therapy without interruption; cycle postponement occurred in 2.5%, pertuzumab discontinuation in 2.5%, and regimen change in 1.3%. TIT incidence was similar with trastuzumab+pertuzumab vs trastuzumab alone (36.8% vs 31.6%; p = 0.68). No baseline demographic, stage, comorbidity, formulation, or regimen variables were associated with TIT risk. Conclusions: In this real-world multicenter UAE cohort, adjuvant trastuzumab ± pertuzumab was associated with a moderate rate of laboratory-defined thrombocytopenia that was usually early-onset and low-grade, with infrequent transfusion or treatment modification, although recurrence occurred in a meaningful minority. Routine platelet monitoring is appropriate; severe or treatment-limiting events appear rare. Logistic regression predicting thrombocytopenia. Predictor Adjusted OR 95% CI p Stage I (vs. II) 0.00 0.00 – ∞ .949 Stage III (vs. II) 1.09 0.32 – 3.72 .890 Regimen: Phesgo SC (vs. Trastuzumab alone) 0.65 0.10 – 4.17 .646 Regimen: T+P IV (vs. Trastuzumab alone) 0.74 0.17 – 3.17 .686 Age (per year) 1.01 0.94 – 1.07 .837 Weight (per kg) 0.99 0.95 – 1.03 .540 Number of cycles 1.02 0.93 – 1.12 .711 Chronic disease (yes vs. no) 0.87 0.24 – 3.10 .828 Baseline platelets <150 3.94 0.29 – 54.35 .305 Note. OR = odds ratio; CI = confidence interval. Reference groups: Stage II, Trastuzumab alone.
No takes yet. Share an insight, caveat, or question.
Abdaljalil et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: